Beschreibung:
Current therapy of metastasized prostate cancer largely depends on androgen-deprivation therapy (ADT). Despite initial response, tumors inevitably reach castration resistance (CRPC), a stage at which chemotherapy and second-generation anti-androgens like Abiraterone and Enzalutamide represent the main remaining therapeutic options. Acquired resistance to these drugs is an emerging problem, raising a need for new approaches. Loss of Chromodomain Helicase DNA binding protein 1 (CHD1) seems to be more prevalent in CRPC compared to earlier tumor stages. In our work, we identified a correlation ...